An increase in the levels of

An increase in the levels of the chemokines CCL-5 and SDF-1 was not noted in either group of women or men with APD as compared with the control group. However, an increase in the levels of the chemokines CCL-5 and SDF-1 was observed in the group of women and men with APD and PTSD versus the group of women and men diagnosed with APD alone. This increase was higher in the case of the chemokine CCL-5 than chemokine SDF-1, and slightly higher in the group of women (2.9 times) than in the group of men (2.7 times). The changes in the chemokine receptors CCR-5 and CXCR-4 in women and men with PTSD are completely different. In the group of women with PTSD alone the level of this Apoptosis Inhibitor increased six times, whereas, in women with APD and PTSD, the level of the receptor CCR-5 was eight times higher than in the control group. Similarly, in men diagnosed only with PTSD, the level of the receptor CCR-5 was three times higher versus the control group. The determined level of that receptor was even higher for men in whom PTSD was accompanied by APD. In this group, the level of the receptor CCR-5 was four times higher than in the control group. In this study, the level of another receptor, CXCR-4, was also determined in representatives of both sexes. It was found that in women with PTSD, regardless of whether it was accompanied by APD or not, the level of that receptor was twice as high as in the control group. The results in the group of men were completely different. Regardless of whether PTSD in men was accompanied by APD or not, no statistically significant differences were found for the receptor CXCR-4 levels in the studied groups, versus the control group. No statistically significant difference was observed in the levels of the chemokine receptors CCR-5 and CXCR-4 either in the group of women or men with APD, excluding PTSD, versus the control group. Nevertheless, an increase in the levels of the chemokine receptors CCR-5 was detected in the group of women and men with APD and PTSD as compared with the group of women and men suffering only from AD. The group of women was observed with a sixfold increase and the group of men with a twofold increase. With regards to the chemokine receptors CXCR-4, a double increase in their levels was recorded in the group of women with APD concurrent with PTSD as compared with the group of women with APD, and with PTSD ruled out. No statistically significant difference was observed, though, between men with APD and PTSD versus men with APD. The statistical assessment also covered changes in the levels of the studied chemokines in women versus men. The analyses of the obtained values indicated statistically significant differences in the chemokine levels between women and men diagnosed with PTSD and APD. In the group of subjects with PTSD and APD, the levels of chemokines CCL-5 and SDF-1 were higher in the group of women versus men. These differences were statistically significant, with the level of significance p=0.0012 for CCL-5 and p=0.0031 for SDF-1. Similarly, in the subjects with only PTSD, higher levels of chemokines CCL-5 and SDF-1 were found in women versus men.